Alexander M.M. Eggermont, MD, PhD, on Melanoma: Advances in Adjuvant Therapy and Guideline Recommendations
Posted: Saturday, October 20, 2018
Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanoma, and what the NCCN Guidelines recommend in light of such data as results on dabrafenib plus trametinib vs anti–PD-1 treatments (nivolumab or pembrolizumab) and the new standard for wild-type disease.